Chris Viehbacher to leave GlaxoSmithKline

Share this article:

Chris Viehbacher, GlaxoSmithKline's executive director and president, North American pharmaceuticals, has announced plans to leave the company.

Viehbacher resigned his position on GSK's board on Sept 8, and will leave the company entirely on December 1, 2008, according to a statement. Andrew Witty, currently CEO at GSK, was appointed to that position upon the retirement of CEO Jean-Pierre Garnier last May. Viehbacher had been a contender for the CEO role. 

Witty said of Viehbacher in the statement, “I would like to thank Chris for his significant contribution to GSK, he is one of the most talented and respected executives in this industry and we wish him well in his future endeavors.”

Share this article:

Email Newsletters

More in News

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...

Bayer drug gets orphan label

Bayer drug gets orphan label

The FDA designation is for an experimental, inhaled form of ciprofloxacin intended to treat a rare lung condition.

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.